{"version":"1.0","provider_name":"IFPMA","provider_url":"https:\/\/www.ifpma.org","title":"Revitalizing the antibiotic pipeline by implementing new R&D pull incentives | IFPMA","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"S1BwWBhm1K\"><a href=\"https:\/\/www.ifpma.org\/publications\/revitalizing-the-antibiotic-pipeline-by-implementing-new-rd-pull-incentives\/\">Revitalizing the antibiotic pipeline by implementing new R&#038;D pull incentives<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.ifpma.org\/publications\/revitalizing-the-antibiotic-pipeline-by-implementing-new-rd-pull-incentives\/embed\/#?secret=S1BwWBhm1K\" width=\"600\" height=\"338\" title=\"&#8220;Revitalizing the antibiotic pipeline by implementing new R&#038;D pull incentives&#8221; &#8212; IFPMA\" data-secret=\"S1BwWBhm1K\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2025\/09\/AMR-incentives-cover.png","thumbnail_width":634,"thumbnail_height":896,"description":"With the 2024 UN High-Level Meeting on antimicrobial resistance (AMR) and its political declaration, together with the biennial AMR Ministerial Meeting, the world has set an ambitious agenda to tackle AMR. The next four years offer renewed political momentum to deliver progress ahead of the next UN High-Level Meeting on AMR in 2029. A central priority is creating the necessary policy frameworks that stimulate R&D investment.  This brief identifies the key barriers to antibiotic R&D and the policy measures needed to address them.\u00a0 Sustainable, effective pull incentives are urgently required to ensure a reliable pipeline of new antibiotics for patients and health systems. We set out how these incentives should be designed and implemented, guided by a set of core principles to maximize their impact."}